Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques

被引:185
作者
Nilsson, T
Longmore, J
Shaw, D
Pantev, E
Bard, JA
Branchek, T
Edvinsson, L [1 ]
机构
[1] Univ Lund Hosp, Dept Internal Med, Div Expt Vasc Res, S-22185 Lund, Sweden
[2] Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England
[3] Synapt Pharmaceut, Paramus, NJ 07652 USA
关键词
coronary artery; human; pharmacology; in vitro; RT-PCR; immunocytochemistry; 5-HT1B receptor; 5-HT2A receptor;
D O I
10.1016/S0014-2999(99)00114-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
5-Hydroxytryptamine (5-HT) can produce both vasoconstrictor and vasorelaxant effects in human coronary arteries and the response to 5-HT can be influenced by the presence of disease, The aim of the present study was to elucidate the 5-HT receptor subtypes responsible for mediating 5-HT-evoked contraction of human coronary arteries using pharmacological, molecular and immunocytochemical approaches. Normal human coronary arteries, with intact endothelium, were mounted in tissue baths, and the vascular responses to 5-HT and 5-HT receptor agonists were studied. The effects of 5-HT1 and 5-HT2 receptor antagonists on these responses were also studied. Expression of messenger ribonucleic acid (mRNA) encoding different 5-HT receptors in human coronary arteries, atrium, ventricle wall and epicardium was determined using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis. The expression of 5-HT1B or 5-HT1D receptor protein was studied using subtype selective antibodies and standard immunocytochemical techniques. The rank order of 5-HT receptor agonist potency in causing vasoconstriction was 5-carboxamido tryptamine, (5-CT) > zolmitriptan = BW183C91 (N-10-desmethyl zolmitriptan) = alpha-methyl-5-hydroxytryptamine (alpha-CH3-5-HT) = 5-HT = sumatriptan > 2-methyl-5-hydroxytryptamine (2-CH3-5-HT) = 8-hydroxy-DPAT (8-OH-DPAT). alpha-CH3-5-HT, 5-CT, 5-HT, zolmitriptan and BW 183C91 were significantly more potent (approximately 3-fold) than sumatriptan and 2-CH3-5-HT, which in turn were more potent than 8-OH-DPAT, Ketanserin and methiothepin (5-HT2 and 5-HT1 receptor antagonists, respectively) caused parallel rightward shifts of the concentration-effect curves to alpha-CH3-5-HT or 5-CT, respectively, without changing the maximum contractile response. In human coronary arteries, atrium, ventricle and epicardium. RT-PCR products corresponding to the human 5-HT2A, 5-HT1B and 5-HT1F receptors were expressed in high levels, mRNAs coding for 5-HT7, 5-HT1A and 5-HT1D receptors were only weakly expressed. No 5-HT1E receptor mRNA was detected. In coronary arteries there was a differential expression of 5-HT1B versus 5-HT1D receptor mRNAs, with 5-HT1B mRNAs being found in greater abundance. Dense 5-HT1B-immunoreactivity was detected on smooth muscle layer within coronary artery, however, 5-HT1D-immunoreactivity was not detected. It is concluded that 5-HT-evoked contraction of human coronary arteries is most probably mediated via the activation of both 5-HT1B and 5-HT2A receptors. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 31 条
[1]   CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F) - A 5TH 5-HT1 RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE-CYCLASE [J].
ADHAM, N ;
KAO, HT ;
SCHECHTER, LE ;
BARD, J ;
OLSEN, M ;
URQUHART, D ;
DURKIN, M ;
HARTIG, PR ;
WEINSHANK, RL ;
BRANCHEK, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :408-412
[2]  
BARD JA, 1993, J BIOL CHEM, V268, P23422
[3]   5-HT RECEPTORS MEDIATING CONTRACTIONS OF THE ISOLATED HUMAN CORONARY-ARTERY [J].
BAX, WA ;
RENZENBRINK, GJ ;
VANHEUVENNOLSEN, D ;
THIJSSEN, EJM ;
BOS, E ;
SAXENA, PR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 239 (1-3) :203-210
[4]  
BRANCHEK T, 1993, MED CHEM RES, V3, P287
[5]   THE SAFETY AND TOLERABILITY OF SUMATRIPTAN - AN OVERVIEW [J].
BROWN, EG ;
ENDERSBY, CA ;
SMITH, RN ;
TALBOT, JCC .
EUROPEAN NEUROLOGY, 1991, 31 (05) :339-344
[6]   5-HYDROXYTRYPTAMINE CONTRACTS HUMAN CORONARY-ARTERIES PREDOMINANTLY VIA 5-HT2 RECEPTOR ACTIVATION [J].
CONNOR, HE ;
FENIUK, W ;
HUMPHREY, PPA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 161 (01) :91-94
[7]  
CONNOR HE, 1996, MIGRAINE PHARM GENET, P18
[8]   The clinical pharmacokinetics of zolmitriptan [J].
Dixon, R ;
Warrander, A .
CEPHALALGIA, 1997, 17 :15-20
[9]  
FENUIK W, 1985, BRIT J PHARMACOL, V86, P697
[10]   A COMPARISON OF THE CONTRACTILE EFFECTS OF 5-HYDROXYTRYPTAMINE, SUMATRIPTAN AND MK-462 ON HUMAN CORONARY-ARTERY IN-VITRO [J].
FERRO, A ;
LONGMORE, J ;
HILL, RG ;
BROWN, MJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) :245-251